[Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m(2) for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later.
Sabugo
Francisca
F
Sección de Reumatología, Departamento de Medicina, Hospital Clínico, Universidad de ChileChile.
Llanos
Carolina
C
Soto
Lilian
L
Gutiérrez
Jorge
J
Cuchacovich
Miguel
M
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab